IL-23 inhibitors used to treat psoriasis patients are associated with the lowest risk of paradoxical AD compared to other biologics.

The AAAAI/ACAAI JTF has published updated AD guidelines based on new available treatments and evidence-based recommendations.

Abrocitinib is efficacious and well tolerated in AD patients with or without allergic comorbidities.

Pain and pruritus are the main contributors to AD burden and poor health-related QoL.

A survey from the National Eczema Association in the U.S. has revealed that patients with AD tend to experience poor mental health symptoms.

The use of dupilumab in patients with AD did not significantly affect the results of patch tests for allergic contact dermatitis.

A research study from Vienna has reported that bacteriophages found in the skin microbiome of patients with AD may lead to the...

Findings from a cross-sectional study of survey data suggest that U.S. sexual and gender minority (SGM) patients with chronic...